2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Pau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Pau Montesinos, MD, PhD, attending physician, hematologist, University Hospital La Fe, Valencia, Spain, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia (AML).
The phase 2 QUIWI trial (NCT04107727) was designed to compare event-free survival (EFS) outcomes with the combination vs placebo. The trial was composed of a safety run-in portion followed by a double-blind randomization phase. Patients with newly diagnosed FLT3-ITD wild-type AML who were fit for intensive chemotherapy were enrolled on the trial and stratified according to age. Notably, these patients were centrally screened for FLT3-ITD before being randomized 2:1 to the experimental vs control regimen.
Early efficacy data from the first interim analysis of this trial were reported at the 2023 EHA Congress. At a median follow-up 21 months, the quizartinib combination produced a median EFS of 16.5 months vs 10.6 months with placebo (HR, 0.741; 95% CI, 0.535-1.026; 2-sided P= .059), Montesinos reports. This indicates a trend towards improved EFS with the combination, he says. Significant improvement in relapse-free survival (RFS) was also observed, Montesinos adds. Median RFS was 18.6 months with placebo and was not reached with quizartinib plus chemotherapy.
Moreover, the 3-year overall survival (OS) rate was approximately 40% in the placebo arm and 60% in the experimental arm, Montesinos continues. Median OS was 20.2 months with placebo and was not reached with the combination (HR, 0.569; 95% CI, 0.385-0.841; 2-sided P= .004).
The composite complete response (cCR) rates were comparable in both arms, Montesinos states. After 1 or 2 induction cycles, the cCR rate was 78% in both study arms, while the CR/CR with incomplete hematologic recovery rate with minimal residual disease (MRD) negativity was 44% vs 43% with the combination and placebo, respectively. Although the regimen did not improve cCR rates vs placebo, significant increases in both EFS and RFS indicate its potential long-term benefit in this population, Montesinos concludes.